Related Experiment Video
Updated: Jun 23, 2026
08:32
Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker
Published on: December 18, 2014
Nebivolol: a third-generation beta-blocker for hypertension.
1Massachusetts College of Pharmacy and Health Sciences, Boston, Massachusetts 02115, USA. judy.cheng@mcphs.edu
Clinical Therapeutics
|April 28, 2009
Summary
Nebivolol effectively lowers blood pressure in hypertension and shows promise for reducing mortality in heart failure patients. This beta-blocker is well-tolerated, offering potential advantages for specific patient groups.
Area of Science:
- Pharmacology and Therapeutics
- Cardiovascular Medicine
Background:
- Nebivolol is a third-generation beta(1)-selective beta-blocker.
- It is approved for hypertension treatment.
Purpose of the Study:
- Review nebivolol's clinical pharmacology.
- Evaluate its efficacy and safety in hypertension and heart failure.
Main Methods:
- Searched MEDLINE and Current Contents (1966-2008).
- Included human clinical trials.
- Reviewed conference abstracts (2006-2008).
Main Results:
- Nebivolol demonstrated comparable blood pressure lowering to other antihypertensives.
- A study indicated a 14% reduction in mortality/hospitalization for heart failure.
- Common side effects included fatigue and headache; it was generally well-tolerated.
Conclusions:
- Nebivolol is effective and well-tolerated for hypertension.
- Preliminary data suggest potential mortality benefits in heart failure.
Related Concept Videos
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
01:28Antihypertensive Drugs: Types of β-Blockers
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:17Antihypertensive Drugs: Action of β1 Blockers
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...